Epidemiology and Treatment of Trichomoniasis

详细信息    查看全文

• 作者：Patricia Kissinger
• 关键词：Trichomonas vaginalis ; Trichomoniasis ; Epidemiology ; Treatment
• 刊名：Current Infectious Disease Reports
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：17
• 期：6
• 全文大小：237 KB
• 参考文献：Papers of particular interest, published recently, have been highlighted as: ??Of importance1.Harp DF, Chowdhury I. Trichomoniasis: evaluation to execution. Eur J Obstet Gynecol Reprod Biol. 2011;157(1):3-.PubMed
  2.Carlton JM et al. Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis. Science. 2007;315(5809):207-2.PubMed Central PubMed
  3.Petrin D et al. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998;11(2):300-7.PubMed Central PubMed
  4.Krieger JN. Trichomoniasis in men: old issues and new data. Sex Transm Dis. 1995;22(2):83-6.PubMed
  5.Burch TA, Rees CW, Reardon L. Diagnosis of Trichomonas vaginalis vaginitis. Am J Obstet Gynecol. 1959;77(2):309-3.PubMed
  6.Charles SX. Epidemiology of trichomonas vaginalis (TV) in rural adolescent and juvenile children. J Trop Pediatr. 1991;37(2):90.PubMed
  7.Adu-Sarkodie Y. Trichomonas vaginalis transmission in a family. Genitourin Med. 1995;71(3):199-00.PubMed Central PubMed
  8.Crucitti T et al. Non-sexual transmission of Trichomonas vaginalis in adolescent girls attending school in Ndola, Zambia. PLoS One. 2011;6(1):e16310.PubMed Central PubMed
  9.Sutton M et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-004. Clin Infect Dis. 2007;45(10):1319-6.PubMed
  10.Sena AC et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007;44(1):13-2.PubMed
  11.Wolner-Hanssen P et al. Clinical manifestations of vaginal trichomoniasis. JAMA. 1989;261(4):571-.PubMed
  12.Martinez-Garcia F et al. Protozoan infections in the male genital tract. J Urol. 1996;156(2 Pt 1):340-.PubMed
  13.Allsworth JE, Ratner JA, Peipert JF. Trichomoniasis and other sexually transmitted infections: results from the 2001-004 National Health and Nutrition Examination Surveys. Sex Transm Dis. 2009;36(12):738-4.PubMed Central PubMed
  14.Silver BJ et al. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis. 2014;41(6):369-6.PubMed
  15.Mann JR et al. Trichomoniasis in pregnancy and mental retardation in children. Ann Epidemiol. 2009;19(12):891-.PubMed
  16.Schwandt A, Williams C, Beigi RH. Perinatal transmission of Trichomonas vaginalis: a case report. J Reprod Med. 2008;53(1):59-1.PubMed
  17.Carter JE, Whithaus KC. Neonatal respiratory tract involvement by Trichomonas vaginalis: a case report and review of the literature. Am J Trop Med Hyg. 2008;78(1):17-.PubMed
  18.Temesvari P et al. Demonstration of Trichomonas vaginalis in tracheal aspirates in infants with early respiratory failure. J Matern Fetal Neonatal Med. 2002;11(5):347-.PubMed
  19.-/div>Kissinger P, Adamski A. Trichomoniasis and HIV interactions: a review. Sex Transm Infect. 2013;89(6):426-3. This study is a comprehensive review of the how T. vaginalis influences both transmission and acquisition of HIV.PubMed Central PubMed
  20.Sardana S et al. Epidemiologic analysis of Trichomonas vaginalis infection in inflammatory smears. Acta Cytol. 1994;38(5):693-.PubMed
  21.Guenthner PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun. 2005;73(7):4155-0.PubMed Central PubMed
  22.Moodley P, Connolly C, Sturm AW. Interrelationships among human immunodeficiency virus type 1 infection, bacterial vaginosis, trichomoniasis, and the presence of yeasts. J Infect Dis. 2002;185(1):69-3.PubMed
  23.van de Wijgert JH et al. Disentangling contributions of reproductive tract infections to HIV acquisition in African women. Sex Transm Dis. 2009;36(6):357-4.PubMed
  24.Sorvillo F, Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet. 1998;351(9097):213-.PubMed
  25.Chesson HW, Blandford JM, Pinkerton SD. Estimates of the annual number and cost of new HIV infections among women attributable to trichomoniasis in the United States. Sex Transm Dis. 2004;31(9):547-1.PubMed
  26.McClelland RS. Trichomonas vaginalis infection: can we afford to do nothing? J Infect Dis. 2008;197(4):487-.PubMed
  27.Price MA et al. The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi. J Acquir Immune Defic Syndr. 2006;43(2):202-.PubMed
  28.Sorvillo F et al. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis. 2001;7(6):927-2.PubMed Central PubMed
  29.Price MA et al. Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis. 2003;30(6):516-2.PubMed
  30.Wang CC et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infec
• 作者单位：Patricia Kissinger (1)
  
  1. School of Public Health and Tropical Medicine, Tulane University, 1440 Canal Street SL-18, New Orleans, LA, 70112, USA
  
• 刊物主题：Infectious Diseases;
• 出版者：Springer US
• ISSN：1534-3146

文摘

Trichomonas vaginalis is the most common nonviral sexually transmitted infection (STI) in the world. It was once thought to be a nuisance STI, but it is now being recognized as an important source of reproductive morbidity and a facilitator of HIV transmission and acquisition, and thus it is an important public health problem. The prevalence of T. vaginalis varies greatly by geography and risk group, but is more common among persons of African descent and appears to increase with age, though this may be a screening phenomenon. Wet mount and culture are simple diagnostics, but have lower sensitivity than nucleic acid amplification techniques presently approved for women only. Single dose (2?g) metronidazole (MTZ) for both the index patient and their sexual partners is the preferred treatment. High rates of retest positivity are found after single-dose treatment which are likely due to clinical resistance rather than re-infection and/or drug resistance.